Kingston Health Sciences Centre Research Institute (KHSC-RI) has launched the first-ever Health Canada-approved clinical trial studying at-home micro-dose use of psilocybin to treat Generalized Anxiety Disorder (GAD).
The Phase 2a study will recruit 60 adults with GAD to test whether daily, non-hallucinogenic doses of psilocybin can safely and effectively ease anxiety symptoms. Participants will take the treatment at home for four weeks, followed by an extension or placebo.
“This represents a major shift — a new way of targeting anxiety without sedation or emotional numbing,” said Dr. Claudio Soares, principal investigator at KHSC-RI.
GAD affects more than 1.6 million Canadians, and many patients face limited treatment options.
Supported by Southeastern Ontario Academic Medical Organization and Diamond Therapeutics, the trial marks a milestone in mental health research.
People living with GAD who want to learn more or participate can contact the research team by email.
Story by Alyssa Brush
Snowbirds set to give Kingston one more spectacular look at the iconic Tutor jets
Police using coordinated approach to address open-air drug use in Kingston
This Canadian program is helping more girls see themselves in tech
Kingston children of all abilities now have new place to play
Bobs Lake marine patrol leads to two impaired operation charges
